TCA
ALNY icon

Trifecta Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Trifecta Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7
Closed -$2.28K – 441
2025
Q2 		$2.28K Buy
+7
New +$1.94K ﹤0.01% 326

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Trifecta Capital Advisors's ALNY Position: Q3 2025 in Review

Trifecta Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 7 shares — an estimated $2.28K sold.

Trifecta Capital Advisors first reported a position in ALNY in Q2 2025 and held it in 1 quarter. The position peaked at $2.28K in Q2 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Trifecta Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Trifecta Capital Advisors sold 7 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $2.28K.
  • Trifecta Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Trifecta Capital Advisors's Alnylam Pharmaceuticals position peaked at $2.28K in Q2 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Trifecta Capital Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.